13710-19-5 Usage
Description
N-(3-Chloro-ortho-tolyl) anthranilic acid, also known as Tolfenamic acid, is an anthranilic acid derivative and a non-steroidal anti-inflammatory drug (NSAID). It is characterized by its white solid appearance and is known for its anti-inflammatory, analgesic, and anticancer properties.
Uses
Used in Pharmaceutical Industry:
N-(3-Chloro-ortho-tolyl) anthranilic acid is used as an anti-inflammatory agent for reducing inflammation and providing analgesia. It is particularly effective in treating conditions such as pancreatic, esophageal, colorectal, and lung cancer.
Used in Neurology:
As a migraine pain reliever, N-(3-Chloro-ortho-tolyl) anthranilic acid is used to alleviate the pain associated with migraines, improving the quality of life for those who suffer from this condition.
Used in Endocrinology:
N-(3-Chloro-ortho-tolyl) anthranilic acid is used as an amidated GRF fragment, which is equipotent to GRF in the release of somatotropin from the anterior pituitary. This application aids in the regulation of growth hormone production.
Used in Neuroscience:
N-(3-Chloro-ortho-tolyl) anthranilic acid is used to inhibit the synthesis of β-amyloid precursor protein and Aβ peptides by promoting the degradation of an essential transcription factor. This makes it a potential therapeutic agent for neurodegenerative diseases associated with amyloid plaque formation.
Used in Hematology:
N-(3-Chloro-ortho-tolyl) anthranilic acid is used to inhibit fMLPand A23187-induced Ca2+ influx in human PMNL with an IC50 value of approximately 20 μM, which can be beneficial in managing certain blood-related conditions.
Used in General Medicine:
As a non-steroidal anti-inflammatory drug (NSAID), N-(3-Chloro-ortho-tolyl) anthranilic acid is used for its broad anti-inflammatory and analgesic effects, making it a versatile option for various medical applications.
Biochem/physiol Actions
Non-steroidal anti-inflammatory agent. Interferes with synthesis of β-amyloid precursor protein, and thus Aβ peptides, by promoting degradation of an essential transcription factor.
Clinical Use
NSAID: Treatment of migraine
Veterinary Drugs and Treatments
Tolfenamic acid may be useful for the treatment of acute or chronic
pain and/or inflammation in dogs and acute pain/inflammation in
cats. In Europe, it is also approved for use in cattle.
Drug interactions
Potentially hazardous interactions with other drugs
ACE inhibitors and angiotensin-II antagonists:
antagonism of hypotensive effect; increased risk of
nephrotoxicity and hyperkalaemia.
Analgesics: avoid concomitant use of 2 or more
NSAIDs, including aspirin (increased side effects);
avoid with ketorolac (increased risk of side effects
and haemorrhage).
Antibacterials: possibly increased risk of convulsions
with quinolones.
Anticoagulants: effects of coumarins and
phenindione enhanced; possibly increased risk of
bleeding with heparins, dabigatran and edoxaban.
Antidepressants: increased risk of bleeding with
SSRIs and venlafaxine.
Antidiabetic agents: effects of sulphonylureas enhanced.
Antiepileptics: possibly increased phenytoin
concentration.
Antivirals: increased risk of haematological toxicity
with zidovudine; concentration possibly increased by
ritonavir.
Ciclosporin: may potentiate nephrotoxicity.
Cytotoxics: reduced excretion of methotrexate;
increased risk of bleeding with erlotinib.
Diuretics: increased risk of nephrotoxicity;
antagonism of diuretic effect; hyperkalaemia with
potassium-sparing diuretics.
Lithium: excretion decreased.
Pentoxifylline: increased risk of bleeding.
Tacrolimus: increased risk of nephrotoxicity
Metabolism
Tolfenamic acid is metabolised in the liver; the metabolites and unchanged drug are conjugated with glucuronic acid. About 90% of an ingested dose is excreted in the urine and the remainder in the faeces.
Check Digit Verification of cas no
The CAS Registry Mumber 13710-19-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,3,7,1 and 0 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 13710-19:
(7*1)+(6*3)+(5*7)+(4*1)+(3*0)+(2*1)+(1*9)=75
75 % 10 = 5
So 13710-19-5 is a valid CAS Registry Number.
InChI:InChI=1/C14H12ClNO2/c1-9-11(15)6-4-8-12(9)16-13-7-3-2-5-10(13)14(17)18/h2-8,16H,1H3,(H,17,18)
13710-19-5Relevant articles and documents
Anti-inflammatory, antiproliferative, and radical-scavenging activities of tolfenamic acid and its metal complexes
Kovala-Demertzi, Dimitra,Hadjipavlou-Litin, Dimitra,Primikiri, Alexandra,Staninska, Malgorzata,Kotoglou, Chronis,Demertzis, Mavroudis A.
, p. 948 - 960 (2009)
Some new complexes of tolfenamic acid (=2-[(2-methyl-3-chlorophenyl)amino] benzoic acid; Htolf) with potentially interesting biological activities are described. The complexes [Mn(tolf)2(H2O)2], [Co(tolf)2(H2O)2], [Ni(tolf2(H 2O)2], [Cu(tolf)2(H2O)]2 , and [Zn(tolf)2(H2O)] were prepared by the reaction of tolfenamic acid, a potent anti-inflammatory drug, with metal salts. The radical-scavenging activities of the complexes were evaluated using the 1,1-diphenyl-2-picrylhydrazyl (DPPH) free radical-scavenging assay. Their ability to inhibit soybean lipoxygenase, β-glucuronidase, and trypsin-induced proteolysis was studied. Their inhibitory effects on rat paw edema induced by carrageenin was studied and compared with those of tolfenamic acid. The complex [Zn(tolf)2(H2O)] exhibited the strongest in vivo inhibitory effect at 0.1 mm/kg Body Weight (BW; 93.0±0.9%), superior than the inhibition induced by tolfenamic acid at the same molar dose (76.0±0.9%). Tolfenamic acid and its metal complexes have been evaluated for antiproliferative activity in vitro against the cells of three human cancer cell lines, MCF-7 (breast cancer cell line), T24 (bladder cancer cell line), and A-549 (non-small cell lung carcinoma), and a mouse fibroblast L-929 cell line. The complexes [Mn(tolf)2(H2O)2] and [Cu-(tolf)2(H2O)]2 have shown selectivity against T24 cell line. The IC50 values of these two complexes against T24 cancer cell lines are in a micromolar range similar or better to that of the antitumor drug cisplatin.
Melatonin derivatives combat with inflammation-related cancer by targeting the Main Culprit STAT3
Ma, Shumeng,Zhu, Longqing,Fan, Xiaohong,Luo, Tian,Liu, Dan,Liang, Ziyi,Hu, Xiaoling,Shi, Tao,Tan, Wen,Wang, Zhen
, (2020/12/02)
The combination between two well-studied bioactive compounds melatonin and salicylic acid with proper modifications unexpectedly creates a sharp pair of “scissors” cutting off the vicious connection between inflammation and cancer by targeting a key contributor Signal Transducers and Activators of Transcription 3 (STAT3) in the two pathological processes. A representative compound P-3 with IC50 values on each tested cell line ranging from 7.37 to 18.62 μM among the designed melatonin derivatives is equipped with the ability of curbing inflammation-promoting cancer by down-regulating the expression, activation and nuclear translocation of STAT3, breaking the feedforward loop of STAT3 activation by decreasing the expression of pro-tumorigenic cytokines, and inducing cell apoptosis through ROS triggered Cyto-c/Caspase-3 pathway. This study suggests that the melatonin derivative P-3 is likely to become a promising chemical structure for developing the novel anti-cancer agents taking effect through hindering the mutual-promoting processes between inflammation and cancer.
OXOACRIDINYL ACETIC ACID DERIVATIVES AND METHODS OF USE
-
Page/Page column 199, (2019/06/05)
Compounds of Formula I or pharmaceutically acceptable salts or esters thereof capable of binding to and modulating the activity of a stimulator of interferon genes (STING) protein are provided. Methods involving compounds of Formula I as effective modulators of STING are also provided.